IBIO INC (IBIO) Fundamental Analysis & Valuation

NASDAQ:IBIO • US4510337086

Current stock price

2.09 USD
-0.01 (-0.48%)
At close:
2.12 USD
+0.03 (+1.44%)
After Hours:

This IBIO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. IBIO Profitability Analysis

1.1 Basic Checks

  • In the past year IBIO has reported negative net income.
  • IBIO had a negative operating cash flow in the past year.
  • In the past 5 years IBIO always reported negative net income.
  • In the past 5 years IBIO always reported negative operating cash flow.
IBIO Yearly Net Income VS EBIT VS OCF VS FCFIBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M

1.2 Ratios

  • IBIO has a Return On Assets of -38.42%. This is comparable to the rest of the industry: IBIO outperforms 58.54% of its industry peers.
  • Looking at the Return On Equity, with a value of -43.74%, IBIO is in the better half of the industry, outperforming 68.14% of the companies in the same industry.
Industry RankSector Rank
ROA -38.42%
ROE -43.74%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBIO Yearly ROA, ROE, ROICIBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600

1.3 Margins

  • IBIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IBIO Yearly Profit, Operating, Gross MarginsIBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. IBIO Health Analysis

2.1 Basic Checks

  • IBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • IBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IBIO Yearly Shares OutstandingIBIO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K
IBIO Yearly Total Debt VS Total AssetsIBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M

2.2 Solvency

  • Based on the Altman-Z score of -2.43, we must say that IBIO is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -2.43, IBIO perfoms like the industry average, outperforming 47.98% of the companies in the same industry.
  • There is no outstanding debt for IBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.43
ROIC/WACCN/A
WACC9.03%
IBIO Yearly LT Debt VS Equity VS FCFIBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 9.04 indicates that IBIO has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 9.04, IBIO is in the better half of the industry, outperforming 77.54% of the companies in the same industry.
  • IBIO has a Quick Ratio of 9.04. This indicates that IBIO is financially healthy and has no problem in meeting its short term obligations.
  • IBIO has a better Quick ratio (9.04) than 77.54% of its industry peers.
Industry RankSector Rank
Current Ratio 9.04
Quick Ratio 9.04
IBIO Yearly Current Assets VS Current LiabilitesIBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. IBIO Growth Analysis

3.1 Past

  • IBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.83%, which is quite impressive.
  • Looking at the last year, IBIO shows a very negative growth in Revenue. The Revenue has decreased by -20.00% in the last year.
  • Measured over the past years, IBIO shows a very negative growth in Revenue. The Revenue has been decreasing by -24.59% on average per year.
EPS 1Y (TTM)53.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.25%
Revenue 1Y (TTM)-20%
Revenue growth 3Y-40.3%
Revenue growth 5Y-24.59%
Sales Q2Q%-100%

3.2 Future

  • Based on estimates for the next years, IBIO will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.09% on average per year.
  • Based on estimates for the next years, IBIO will show a small growth in Revenue. The Revenue will grow by 4.56% on average per year.
EPS Next Y83.78%
EPS Next 2Y35.73%
EPS Next 3Y20.95%
EPS Next 5Y11.09%
Revenue Next Year0%
Revenue Next 2Y-20.94%
Revenue Next 3Y7.72%
Revenue Next 5Y4.56%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IBIO Yearly Revenue VS EstimatesIBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 50M 100M 150M
IBIO Yearly EPS VS EstimatesIBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -100 -200 -300

More info and screens

Find the best growth stocksShow best growing peers

1

4. IBIO Valuation Analysis

4.1 Price/Earnings Ratio

  • IBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year IBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IBIO Price Earnings VS Forward Price EarningsIBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IBIO Per share dataIBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

  • IBIO's earnings are expected to grow with 20.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.73%
EPS Next 3Y20.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IBIO Dividend Analysis

5.1 Amount

  • No dividends for IBIO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IBIO Fundamentals: All Metrics, Ratios and Statistics

IBIO INC

NASDAQ:IBIO (3/20/2026, 8:00:11 PM)

After market: 2.12 +0.03 (+1.44%)

2.09

-0.01 (-0.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-10
Earnings (Next)04-30
Inst Owners45.88%
Inst Owner Change351.05%
Ins Owners2.32%
Ins Owner Change0%
Market Cap72.19M
Revenue(TTM)300.00K
Net Income(TTM)-24.74M
Analysts85.45
Price Target4.61 (120.57%)
Short Float %12.37%
Short Ratio2.08
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-6.08%
Min EPS beat(2)-6.95%
Max EPS beat(2)-5.21%
EPS beat(4)0
Avg EPS beat(4)-23.48%
Min EPS beat(4)-50.12%
Max EPS beat(4)-5.21%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)96.08%
Min Revenue beat(2)-100%
Max Revenue beat(2)292.16%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.24%
EPS NQ rev (1m)-1.9%
EPS NQ rev (3m)32.25%
EPS NY rev (1m)12.16%
EPS NY rev (3m)29.83%
Revenue NQ rev (1m)-20%
Revenue NQ rev (3m)-20%
Revenue NY rev (1m)14.29%
Revenue NY rev (3m)33.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 240.63
P/FCF N/A
P/OCF N/A
P/B 1.28
P/tB 1.38
EV/EBITDA N/A
EPS(TTM)-1.18
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.54
OCFYN/A
SpS0.01
BVpS1.64
TBVpS1.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -38.42%
ROE -43.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 77.23%
Cap/Sales 187.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.04
Quick Ratio 9.04
Altman-Z -2.43
F-Score4
WACC9.03%
ROIC/WACCN/A
Cap/Depr(3y)216.31%
Cap/Depr(5y)243.74%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.25%
EPS Next Y83.78%
EPS Next 2Y35.73%
EPS Next 3Y20.95%
EPS Next 5Y11.09%
Revenue 1Y (TTM)-20%
Revenue growth 3Y-40.3%
Revenue growth 5Y-24.59%
Sales Q2Q%-100%
Revenue Next Year0%
Revenue Next 2Y-20.94%
Revenue Next 3Y7.72%
Revenue Next 5Y4.56%
EBIT growth 1Y-63.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.43%
OCF growth 3YN/A
OCF growth 5YN/A

IBIO INC / IBIO Fundamental Analysis FAQ

What is the ChartMill fundamental rating of IBIO INC (IBIO) stock?

ChartMill assigns a fundamental rating of 3 / 10 to IBIO.


What is the valuation status for IBIO stock?

ChartMill assigns a valuation rating of 1 / 10 to IBIO INC (IBIO). This can be considered as Overvalued.


Can you provide the profitability details for IBIO INC?

IBIO INC (IBIO) has a profitability rating of 1 / 10.